View Clinical Trial (Medical Research Study)

[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors - NCT00832598-10065(Clinical Trial 267578)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  New York
State:  
NY
Zip Code: 10065
Conditions: Brain Cancer - Gliomas
Purpose: The purpose of this study is to help us understand gliomas, one type of brain tumor. This research protocol makes pictures of gliomas. We will take pictures of the glioma before and after treatment. The pictures are made with a positron emission tomography (PET) scanner. PET scans use radioactive markers to "see" cancer cells. We plan to use two different radioactive markers, [18F]FACBC and [18F]FLT, to "see" if the glioma responds to the treatment being recommended by the doctor. We are investigating whether one or both of these types of PET scans can help us to better understand gliomas and their response to treatment. We expect these pictures will give us information the your tumor and may help us to understand why the treatment that the patient is receiving is affecting the tumor the way that it is. We also hope to collect information about the amount of radioactivity exposure. We will measure radioactivity exposure to the tumor, brain and other organs.
Study summary:
Criteria: Inclusion Criteria: - Registered patient at MSKCC. - Child-bearing age females must be non-pregnant,(documented by a negative pregnancy test within the last 2 weeks), non-lactating, and must be using adequate contraception or be surgically sterile. - Patients with gliomas - Patients planning to start anti-AKT and/or anti-VEGF directed therapies . - Patients with measurable disease on MRI or CT neuroimaging. Exclusion Criteria: - Patient is incontinent of urine or stool (which would make them unable to tolerate lying still for 60 minutes). - Patient cannot tolerate lying still for a 60 minute session in the PET tomograph.
Study is available at: Memorial Sloan-Kettering Cancer Center
New York, NY 10065
United States

Primary Contact:
Andrew Lassman, MD
Phone: 212-639-6037

Secondary Contact:
Andrew Lassman, MD
Phone: 212-639-6037
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.